Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Esophageal Cancer

8 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMD1605

    03/28/2017

    Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors

    Treatment

    VICCGI1655

    12/14/2016

    A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

    Treatment

    VICCPHI15114

    09/28/2016

    An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    VICCGI1515

    01/05/2016

    A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCGIP1536

    10/26/2015

    A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor